These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 16765164)

  • 1. Cardiovascular effects of androgen depletion and replacement therapy.
    Pinthus JH; Trachtenberg J; Klotz L
    Urology; 2006 Jun; 67(6):1126-32. PubMed ID: 16765164
    [No Abstract]   [Full Text] [Related]  

  • 2. Cardiovascular risk during androgen deprivation therapy for prostate cancer.
    Jones TH
    BMJ; 2011 May; 342():d3105. PubMed ID: 21610041
    [No Abstract]   [Full Text] [Related]  

  • 3. Can exercise ameliorate the increased risk of cardiovascular disease and diabetes associated with ADT?
    Galvão DA; Newton RU; Taaffe DR; Spry N
    Nat Clin Pract Urol; 2008 Jun; 5(6):306-7. PubMed ID: 18431358
    [No Abstract]   [Full Text] [Related]  

  • 4. Androgen deprivation therapy for prostate cancer.
    Bahnson R
    J Urol; 2007 Oct; 178(4 Pt 1):1148. PubMed ID: 17698142
    [No Abstract]   [Full Text] [Related]  

  • 5. Cardiovascular disease with androgen deprivation: the (forgotten) role of testosterone.
    Aragon-Ching JB
    J Clin Oncol; 2009 Dec; 27(35):e261; author reply e262. PubMed ID: 19884519
    [No Abstract]   [Full Text] [Related]  

  • 6. Risk of metabolic syndrome, cardiovascular disease, and diabetes in androgen deprivation therapy.
    Leahy Y
    Clin J Oncol Nurs; 2008 Oct; 12(5):771-6. PubMed ID: 18842533
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiovascular and metabolic complications during androgen deprivation: exercise as a potential countermeasure.
    Galvão DA; Taaffe DR; Spry N; Joseph D; Newton RU
    Prostate Cancer Prostatic Dis; 2009; 12(3):233-40. PubMed ID: 19488067
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolic and cardiovascular effects of androgen deprivation therapy.
    Hakimian P; Blute M; Kashanian J; Chan S; Silver D; Shabsigh R
    BJU Int; 2008 Dec; 102(11):1509-14. PubMed ID: 18727614
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-androgen treatment of prostatic carcinoma may be a risk factor for development of rheumatoid arthritis.
    Pope JE; Joneja M; Hong P
    J Rheumatol; 2002 Nov; 29(11):2459-62. PubMed ID: 12415609
    [No Abstract]   [Full Text] [Related]  

  • 10. Cardiovascular risk in androgen suppression: underappreciated, under-researched and unresolved.
    Bourke L; Chico TJ; Albertsen PC; Hamdy FC; Rosario DJ
    Heart; 2012 Mar; 98(5):345-8. PubMed ID: 22155645
    [No Abstract]   [Full Text] [Related]  

  • 11. Androgen deprivation therapy and cardiovascular complications.
    Poljak Z; Hulin I; Maruscakova L; Carter A; Mladosievicova B
    Bratisl Lek Listy; 2016; 117(10):557-561. PubMed ID: 28621142
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Don't think once, think twice! the cardiovascular effects of androgen deprivation therapy.
    Jefferies ER; Thurairaja R; Persad RA; Rajani R; Phull JS; Bahl A
    BJU Int; 2011 Apr; 107(7):1023-8. PubMed ID: 21438973
    [No Abstract]   [Full Text] [Related]  

  • 13. Androgen deprivation therapy, insulin resistance, and cardiovascular mortality: an inconvenient truth.
    Basaria S
    J Androl; 2008; 29(5):534-9. PubMed ID: 18567642
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Toward the optimal use of androgen suppression therapy in the radiotherapeutic management of prostate cancer.
    D'Amico AV
    J Clin Oncol; 2007 Jan; 25(1):8-9. PubMed ID: 17194901
    [No Abstract]   [Full Text] [Related]  

  • 15. "Staging the aging" when considering androgen deprivation therapy for older men with prostate cancer.
    Dale W
    J Clin Oncol; 2009 Jul; 27(21):3420-2. PubMed ID: 19506150
    [No Abstract]   [Full Text] [Related]  

  • 16. Androgen suppression therapy and prostate cancer: balancing the harms and the benefits.
    Oefelein MG
    Cancer; 2008 Dec; 113(12):3275-8. PubMed ID: 18988289
    [No Abstract]   [Full Text] [Related]  

  • 17. [Efficacy and safety of hormonal therapy with androgens (androgel) in men with erectile dysfunction, partial androgen deficiency of aging male and cardiovascular diseases].
    Kalinchenko SIu; Vorslov LO; Aglamazian NL; Morgunov LIu
    Urologiia; 2007; (1):57, 59-61. PubMed ID: 17472002
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The dark side of testosterone deficiency: III. Cardiovascular disease.
    Traish AM; Saad F; Feeley RJ; Guay A
    J Androl; 2009; 30(5):477-94. PubMed ID: 19342698
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Competing risks for patients with localized prostate cancer.
    Seidenfeld J; Samson DJ; Albertsen PC
    J Natl Cancer Inst; 2007 Oct; 99(20):1498-9. PubMed ID: 17925533
    [No Abstract]   [Full Text] [Related]  

  • 20. Managing the side effects of androgen-deprivation therapy.
    J Support Oncol; 2007 Feb; 5(2):87-8. PubMed ID: 17348368
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.